Metapristone (developmental code name RU-42633; also known as desmethylmifepristone) is the major metabolite of mifepristone (RU-486, RU-38486) and a selective progesterone receptor modulator (SPRM) which itself was never marketed.

[1][5] The metabolite retains partial but considerable affinity for the progesterone receptor (PR) and the glucocorticoid receptor (GR) (RBATooltip relative binding affinity = 21% and 61% of that of mifepristone for the human forms of these receptors, respectively).

[6][1] On the basis of actions that are apparently independent of its hormonal activity, metapristone is being researched as a potential cancer metastatic chemopreventive agent.

You can help Wikipedia by expanding it.This drug article relating to the genito-urinary system is a stub.

You can help Wikipedia by expanding it.This antineoplastic or immunomodulatory drug article is a stub.